The history of the erectile dysfunction drug presents a complex picture for shareholders. While the initial release generated substantial returns, the end of its intellectual property protection opened the door to https://onlybookmarkings.com/story21533136/the-copyright-and-the-pharmaceutical-industry-a-volatile-bet